OAB-035: Minimally invasive profiling of tumor and immune cells to stratify risk in smoldering multiple myeloma (SMM): the iMMunocell study

MLA

Rebeca Iglesias, et al. “OAB-035: Minimally Invasive Profiling of Tumor and Immune Cells to Stratify Risk in Smoldering Multiple Myeloma (SMM): The IMMunocell Study.” Clinical Lymphoma Myeloma and Leukemia, vol. 21, Oct. 2021, pp. S22–23. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........5640fa027567c54626d83861bce9689d&authtype=sso&custid=ns315887.

APA

Rebeca Iglesias, Tomas Jelinek, Evangelos Terpos, Albert Pérez Montaña, Joaquin Martinez-Lopez, Jose Enrique de la Puerta, Roman Hájek, Fernando Solano, Cirino Botta, Jesús F. San-Miguel, Enrique M. Ocio, Juan José Garcés, David Zihala, Hervé Avet-Loiseau, María José Casanova, Bruno Paiva, Hartmut Goldschmidt, Rosalinda Termini, Maria-Elena Cabezudo, … Heinz Ludwig. (2021). OAB-035: Minimally invasive profiling of tumor and immune cells to stratify risk in smoldering multiple myeloma (SMM): the iMMunocell study. Clinical Lymphoma Myeloma and Leukemia, 21, S22–S23.

Chicago

Rebeca Iglesias, Tomas Jelinek, Evangelos Terpos, Albert Pérez Montaña, Joaquin Martinez-Lopez, Jose Enrique de la Puerta, Roman Hájek, et al. 2021. “OAB-035: Minimally Invasive Profiling of Tumor and Immune Cells to Stratify Risk in Smoldering Multiple Myeloma (SMM): The IMMunocell Study.” Clinical Lymphoma Myeloma and Leukemia 21 (October): S22–23. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........5640fa027567c54626d83861bce9689d&authtype=sso&custid=ns315887.